Search

Your search keyword '"Heuser, M"' showing total 849 results
Start Over Author "Heuser, M"
849 results on '"Heuser, M"'

1. Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial

Author

Wilop, S., Tometten, M., Korfel, A., Keller, U., de Wit, M., Weissinger, F., Stark, U., Behringer, D., Bückner, U., Nückel, H., Schroers, R., Trenn, G., Hertenstein, B., Bernhard, H., Heike, M., Wörns, M.-A., Kroschinsky, F., Prange-Krex, G., Giagounidis, A., Grigoleit, G. U., Selbach, J., Petrasch, S., Balleisen, J. S., Schütte, J., Dienst, A., Germing, U., Dührsen, U., von Verschuer, U., Reimer, P., Höffkes, H.-G., Runde, V., Spohn, C., Moeller, R., Dürk, H., Kofahl-Krause, D., Heuser, M., Witzens-Harig, M., Müller-Tidow, C., Martens, U. M., Strumberg, D., La Rosée, P., Hochhaus, A., Link, H., Held, G., Kneba, M., Baldus, C., Naumann, R., Chemnitz, J. M., Schulte, K., Limmroth, C., Schwarzer, A., Niederwieser, D., Platzbecker, U., Heil, G., Schwalenberg, M., Grieshammer, M., Beck, C., Stephany, M., Mesters, R., Karsten, I. E., Held, H., Mahlmann, S., Steiniger, H., Gaska, T., Südhoff, T., Kreisel-Büstgens, C., Moorahrend, E., Maschmeyer, G., Jordan, K., Kloke, O., Klein, M., Höhler, T., Grube, M., Herr, W., Hahn, D., Raghavachar, A., Schmalz, O., Fett, W., Sandmann, M., Krohn, T., Brenner, W., Plotkin, M., Franzius, C., Kotzerke, J., Hautzel, H., Bockisch, A., Hertel, A., Bengel, F. M., Haberkorn, U., Freesmeyer, M., Lützen, U., Klein, A., Kluge, R., Larisch, R., Fricke, E., Holzinger, J., Schäfer, W., Weckesser, M., Nyuyki, F., Römer, W., Brink, I., Marienhagen, J., Pöpperl, G., Jöckel, K.-H., Nonnemacher, M., Rekowski, J., Scherag, A., Neuhäuser, M., Dührsen, Ulrich, Bockisch, Andreas, Hertenstein, Bernd, Karsten, Imke E., Kroschinsky, Frank, Heuser, Michael, Hochhaus, Andreas, Höffkes, Heinz-Gert, Behringer, Dirk, Prange-Krex, Gabriele, Tometten, Mareike, Grieshammer, Martin, Grigoleit, Götz U., Schmalz, Oliver, Jordan, Karin, Bernhard, Helga, Gaska, Tobias, Giagounidis, Aristoteles, Schroers, Roland, Martens, Uwe M., Held, Gerhard, Klapper, Wolfram, Jöckel, Karl-Heinz, Nonnemacher, Michael, and Hüttmann, Andreas

Published
2024
Full Text
View/download PDF

3. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

Author

Buske, C., Dreyling, M., Alvarez-Larrán, A., Apperley, J., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Giovanni Della Porta, M., Dimopoulos, M., D’Sa, S., Eich, H.T., Foà, R., Ghia, P., da Silva, M.G., Gribben, J., Hajek, R., Harrison, C., Heuser, M., Kiesewetter, B., Kiladjian, J.J., Kröger, N., Moreau, P., Passweg, J.R., Peyvandi, F., Rea, D., Ribera, J.-M., Robak, T., San-Miguel, J.F., Santini, V., Sanz, G., Sonneveld, P., von Lilienfeld-Toal, M., Wendtner, C., Pentheroudakis, G., and Passamonti, F.

Published
2022
Full Text
View/download PDF

6. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia

Author

Madan, V, Shyamsunder, P, Han, L, Mayakonda, A, Nagata, Y, Sundaresan, J, Kanojia, D, Yoshida, K, Ganesan, S, Hattori, N, Fulton, N, Tan, K-T, Alpermann, T, Kuo, M-C, Rostami, S, Matthews, J, Sanada, M, Liu, L-Z, Shiraishi, Y, Miyano, S, Chendamarai, E, Hou, H-A, Malnassy, G, Ma, T, Garg, M, Ding, L-W, Sun, Q-Y, Chien, W, Ikezoe, T, Lill, M, Biondi, A, Larson, RA, Powell, BL, Lübbert, M, Chng, WJ, Tien, H-F, Heuser, M, Ganser, A, Koren-Michowitz, M, Kornblau, SM, Kantarjian, HM, Nowak, D, Hofmann, W-K, Yang, H, Stock, W, Ghavamzadeh, A, Alimoghaddam, K, Haferlach, T, Ogawa, S, Shih, L-Y, Mathews, V, and Koeffler, HP

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Human Genome, Childhood Leukemia, Pediatric Cancer, Genetics, Rare Diseases, Hematology, Clinical Research, Pediatric, Cell Differentiation, DNA Mutational Analysis, DNA-Binding Proteins, Exome, Gene Expression Profiling, Humans, Leukemia, Promyelocytic, Acute, Nuclear Proteins, Recurrence, Transcription Factors, Immunology, Cardiovascular medicine and haematology, Clinical sciences, Oncology and carcinogenesis
Abstract

Acute promyelocytic leukemia (APL) is a subtype of myeloid leukemia characterized by differentiation block at the promyelocyte stage. Besides the presence of chromosomal rearrangement t(15;17), leading to the formation of PML-RARA (promyelocytic leukemia-retinoic acid receptor alpha) fusion, other genetic alterations have also been implicated in APL. Here, we performed comprehensive mutational analysis of primary and relapse APL to identify somatic alterations, which cooperate with PML-RARA in the pathogenesis of APL. We explored the mutational landscape using whole-exome (n=12) and subsequent targeted sequencing of 398 genes in 153 primary and 69 relapse APL. Both primary and relapse APL harbored an average of eight non-silent somatic mutations per exome. We observed recurrent alterations of FLT3, WT1, NRAS and KRAS in the newly diagnosed APL, whereas mutations in other genes commonly mutated in myeloid leukemia were rarely detected. The molecular signature of APL relapse was characterized by emergence of frequent mutations in PML and RARA genes. Our sequencing data also demonstrates incidence of loss-of-function mutations in previously unidentified genes, ARID1B and ARID1A, both of which encode for key components of the SWI/SNF complex. We show that knockdown of ARID1B in APL cell line, NB4, results in large-scale activation of gene expression and reduced in vitro differentiation potential.

Published
2016

7. Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine

Author

Schlenk, R. F., Weber, D., Herr, W., Wulf, G., Salih, H. R., Derigs, H. G., Kuendgen, A., Ringhoffer, M., Hertenstein, B., Martens, U. M., Grießhammer, M., Bernhard, H., Krauter, J., Girschikofsky, M., Wolf, D., Lange, E., Westermann, J., Koller, E., Kremers, S., Wattad, M., Heuser, M., Thol, F., Göhring, G., Haase, D., Teleanu, V., Gaidzik, V., Benner, A., Döhner, K., Ganser, A., Paschka, P., and Döhner, H.

Published
2019
Full Text
View/download PDF

8. Operative Aspekte

Author

Chon, S. H., Meyer, H. J., Flohé, S., Weindl, R., Voigt, C., Heuser, M., Follmann, P., Graff†, H. J., Rutt, G. T., Appel, T., Schmickler, St., Sesterhenn, A. M., Geyer, G., Pfaffenbach, B., Standl, Thomas, editor, and Lussi, Christoph, editor

Published
2016
Full Text
View/download PDF

9. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Author

Lyon, A. R., Lopez-Fernandez, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., de Azambuja, E., de Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D., Moslehi, J., Moura, B., Salinger, S. S., Stephens, R., Suter, T. M., Szmit, S., Tamargo, J., Thavendiranathan, P., Tocchetti, C. G., van der Meer, P., van der Pal, H. J. H., Lancellotti, P., Thuny, F., Abdelhamid, M., Aboyans, V., Aleman, B., Alexandre, J., Barac, A., Borger, M. A., Casado-Arroyo, R., Cautela, J., Celutkiene, J., Cikes, M., Cohen-Solal, A., Dhiman, K., Ederhy, S., Edvardsen, T., Fauchier, L., Fradley, M., Grapsa, J., Halvorsen, S., Heuser, M., Humbert, M., Jaarsma, T., Kahan, T., Konradi, A., Koskinas, K. C., Kotecha, D., Ky, B., Landmesser, U., Lewis, B. S., Linhart, A., Lip, G. Y. H., Lochen, M. -L., Malaczynska-Rajpold, K., Metra, M., Mindham, R., Moonen, M., Neilan, T. G., Nielsen, J. C., Petronio, A. -S., Prescott, E., Rakisheva, A., Salem, J. -E., Savarese, G., Sitges, M., Ten Berg, J., Touyz, R. M., Tycinska, A., Wilhelm, M., Zamorano, J. L., Cardiovascular Centre (CVC), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), Group, ESC Scientific Document, Lyon, Alexander R, López-Fernández, Teresa, Couch, Liam S, Asteggiano, Riccardo, Aznar, Marianne C, Bergler-Klein, Jutta, Boriani, Giuseppe, Cardinale, Daniela, Cordoba, Raul, Cosyns, Bernard, Cutter, David J, de Azambuja, Evandro, de Boer, Rudolf A, Dent, Susan F, Farmakis, Dimitrio, Gevaert, Sofie A, Gorog, Diana A, Herrmann, Joerg, Lenihan, Daniel, Moslehi, Javid, Moura, Brenda, Salinger, Sonja S, Stephens, Richard, Suter, Thomas M, Szmit, Sebastian, Tamargo, Juan, Thavendiranathan, Paaladinesh, Tocchetti, Carlo G, van der Meer, Peter, van der Pal, Helena J H, Cardiology, Clinical sciences, and Cardio-vascular diseases

Subjects
Cardiac magnetic resonance, Cancer survivors, Vascular endothelial growth factor inhibitors (VEGFi), Myocarditi, Guideline, Anthracycline, Arrhythmias, Medical Oncology, T-CELL THERAPY, Coronary artery disease, Strain, RECURRENT VENOUS THROMBOEMBOLISM, Amyloid light-chain cardiac amyloidosis, Androgen deprivation therapy, Atrial fibrillation, Biomarkers, Cancer, Carcinoid syndrome, Cardiac tumour, Cardio-oncology, Cardiotoxicity, Chemotherapy, Echocardiography, Fluoropyrimidine, Guidelines, Haematopoietic stem cell transplantation, Heart failure, Hormone therapy, Hypertension, Immunotherapy, Ischaemic heart disease, Myocarditis, Pericardial disease, Proteasome inhibitors, Pulmonary hypertension, QTc prolongation, Radiotherapy, Risk stratification, Thrombosis, Trastuzumab, Valvular heart disease, Venous thromboembolism, Neoplasms, Proteasome inhibitor, Amyloid light-chain cardiac amyloidosi, IMMUNE CHECKPOINT INHIBITORS, Cardiotoxicity/diagnostic imaging, Heart, General Medicine, Hematology, MOLECULAR-WEIGHT HEPARIN, BRAIN NATRIURETIC PEPTIDE, oncology, Cancer survivor, Thrombosi, CORONARY-ARTERY-DISEASE, Cardiology and Cardiovascular Medicine, TYROSINE KINASE INHIBITOR, Arrhythmia, Neoplasms/diagnostic imaging, Antineoplastic Agents, Humans, Radiology, Nuclear Medicine and imaging, EARLY BREAST-CANCER, CARCINOID HEART-DISEASE, Antineoplastic Agents/therapeutic use, Biomarker, AORTIC-VALVE-REPLACEMENT, Radiation Oncology
Published
2022

10. Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES

Author

Bernard, E., primary, Hasserjian, R., additional, Greenberg, P., additional, Ossa, J. Arango, additional, Creignou, M., additional, Nannya, Y., additional, Tuechler, H., additional, Medina-Martinez, J., additional, Levine, M., additional, Jädersten, M., additional, Germing, U., additional, Sanz, G., additional, Van De Loosdrecht, A., additional, Kosmider, O., additional, Follo, M., additional, Thol, F., additional, Zamora, L., additional, Pinheiro, R., additional, Pellagatti, A., additional, Elias, H., additional, Haase, D., additional, Ganster, C., additional, Ades, L., additional, Tobiasson, M., additional, Palomo, L., additional, Della Porta, M., additional, Fenaux, P., additional, Belickova, M., additional, Savona, M., additional, Klimek, V., additional, Santos, F., additional, Boultwood, J., additional, Kotsianidis, I., additional, Santini, V., additional, Solé, F., additional, Platzbecker, U., additional, Heuser, M., additional, Valent, P., additional, Finelli, C., additional, Voso, M.T., additional, Shih, L.-Y., additional, Fontenay, M., additional, Jansen, J., additional, Cervera-Zamora, J., additional, Gattermann, N., additional, Ebert, B., additional, Bejar, R., additional, Malcovati, L., additional, Cazzola, M., additional, Ogawa, S., additional, Hellstrom-Lindberg, E., additional, and Papaemmanuil, E., additional

Published
2023
Full Text
View/download PDF

11. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN DAILY CLINICAL PRACTICE

Author

Schulz, F., primary, Kellersmann, C., additional, Betz, B., additional, Hildebrandt, B., additional, Thol, F., additional, Heuser, M., additional, Ganster, C., additional, Beier, F., additional, Sockel, K., additional, Hofmann, W.-K., additional, Kuendgen, A., additional, Pfeilstoecker, M., additional, Gattermann, N., additional, Nachtkamp, K., additional, Haase, D., additional, and Germing, U., additional

Published
2023
Full Text
View/download PDF

12. 'Fit for the finals' - project report on a telemedical training with simulated patients, peers, and assessors for the licensing exam

Author

Harendza, S, Bußenius, L, Gärtner, J, Heuser, M, Ahles, J, Prediger, S, Harendza, S, Bußenius, L, Gärtner, J, Heuser, M, Ahles, J, and Prediger, S

Abstract

Background: Undergraduate medical students take the licensing exam (M3) as a two-day oral-practical examination. The main requirements are to demonstrate history taking skills and coherent case presentations. The aim of this project was to establish a training in which students can test their communication skills during history taking and their clinical reasoning skills in focused case presentations. Methods: In the newly developed training, final-year students took four telemedical histories in the role of physicians from simulated patients (SP). They received further findings for two SPs and presented these in a handover, in which they also received a handover of two SPs which they had not seen themselves. Each student presented one of the two received SPs in a case discussion with a senior physician. Feedback was given to the participants on their communication and interpersonal skills by the SPs with the ComCare questionnaire and on the case presentation by the senior physician. Sixty-two students from the universities of Hamburg and Freiburg in their final year participated in September 2022 and evaluated the training.Results: Participants felt that the training was very appropriate for exam preparation. The SPs' feedback on communication and the senior physician's feedback on clinical reasoning skills received the highest ratings in importance to the students. Participants highly valued the practice opportunity for structured history taking and case presentation and would like to have more such opportunities in the curriculum.Conclusion: Essential elements of the medical licensing exam can be represented, including feedback, in this telemedical training and it can be offered independent of location., Hintergrund: Den dritten Abschnitt der Ärztlichen Prüfung (M3) absolvieren Medizinstudierende als zweitägige mündlich-praktische Prüfung. Es sind vor allem Anamnesefähigkeiten und schlüssige Fallpräsentationen zu demonstrieren. Ziel dieses Projektes war es, ein Training zu etablieren, in dem Studierende ihre kommunikativen Fähigkeiten in Anamnesegesprächen und ihre Clinical-Reasoning-Fähigkeiten in fokussierten Fallvorstellungen erproben können.Methoden: Im neu entwickelten Training führten PJ-Studierende in der Rolle von Ärzt*innen vier telemedizinische Anamnesegespräche mit Simulationspatient*innen (SP). Zu zwei SPs erhielten sie weitere Befunde und stellten diese in einer Fallübergabe vor, in der sie zwei SPs übergeben bekamen, die sie selbst nicht gesehen hatten. Eine*n der beiden gehörten SPs stellte jede*r in einer Fallbesprechung mit einer Oberärztin vor. Feedback erhielten die Teilnehmenden von den SPs zu ihren kommunikativen und interpersonellen Fähigkeiten mit dem ComCare-Bogen und von der Oberärztin zur Fallpräsentation. Es nahmen 62 PJ-Studierende der Universitäten Hamburg und Freiburg im September 2022 teil und evaluierten das Training.Ergebnisse: Die Teilnehmenden hielten das Training zur Examensvorbereitung für sehr geeignet. Das Feedback der SPs zur Kommunikation und der Oberärztin zu den Clinical-Reasoning-Fähigkeiten erhielt in der Wichtigkeit für die Studierenden die höchsten Bewertungen. Die Teilnehmenden schätzten die Übungsmöglichkeit für strukturierte Anamneseerhebung und Fallpräsentation sehr und wünschten sich mehr solcher Angebote im Studium.Schlussfolgerung: Im telemedizinischen Training lassen sich wesentliche Elemente des Dritten Abschnitts der Ärztlichen Prüfung mit Feedback abbilden und es kann standortunabhängig angeboten werden.

Published
2023

13. 'Fit fürs M3-Examen' - Projektbericht zu einem telemedizinischen Training mit Simulationspatient*innen, Peers und Prüfenden für den Dritten Abschnitt der Ärztlichen Prüfung

Author

Harendza, S, Bußenius, L, Gärtner, J, Heuser, M, Ahles, J, and Prediger, S

Subjects
formative testing, training, ddc: 610, formative Prüfung, exam, telemedicine, simulation, Telemedizin, Examen
Abstract

Background: Undergraduate medical students take the licensing exam (M3) as a two-day oral-practical examination. The main requirements are to demonstrate history taking skills and coherent case presentations. The aim of this project was to establish a training in which students can test their communication skills during history taking and their clinical reasoning skills in focused case presentations. Methods: In the newly developed training, final-year students took four telemedical histories in the role of physicians from simulated patients (SP). They received further findings for two SPs and presented these in a handover, in which they also received a handover of two SPs which they had not seen themselves. Each student presented one of the two received SPs in a case discussion with a senior physician. Feedback was given to the participants on their communication and interpersonal skills by the SPs with the ComCare questionnaire and on the case presentation by the senior physician. Sixty-two students from the universities of Hamburg and Freiburg in their final year participated in September 2022 and evaluated the training.Results: Participants felt that the training was very appropriate for exam preparation. The SPs' feedback on communication and the senior physician's feedback on clinical reasoning skills received the highest ratings in importance to the students. Participants highly valued the practice opportunity for structured history taking and case presentation and would like to have more such opportunities in the curriculum.Conclusion: Essential elements of the medical licensing exam can be represented, including feedback, in this telemedical training and it can be offered independent of location. Hintergrund: Den dritten Abschnitt der Ärztlichen Prüfung (M3) absolvieren Medizinstudierende als zweitägige mündlich-praktische Prüfung. Es sind vor allem Anamnesefähigkeiten und schlüssige Fallpräsentationen zu demonstrieren. Ziel dieses Projektes war es, ein Training zu etablieren, in dem Studierende ihre kommunikativen Fähigkeiten in Anamnesegesprächen und ihre Clinical-Reasoning-Fähigkeiten in fokussierten Fallvorstellungen erproben können.Methoden: Im neu entwickelten Training führten PJ-Studierende in der Rolle von Ärzt*innen vier telemedizinische Anamnesegespräche mit Simulationspatient*innen (SP). Zu zwei SPs erhielten sie weitere Befunde und stellten diese in einer Fallübergabe vor, in der sie zwei SPs übergeben bekamen, die sie selbst nicht gesehen hatten. Eine*n der beiden gehörten SPs stellte jede*r in einer Fallbesprechung mit einer Oberärztin vor. Feedback erhielten die Teilnehmenden von den SPs zu ihren kommunikativen und interpersonellen Fähigkeiten mit dem ComCare-Bogen und von der Oberärztin zur Fallpräsentation. Es nahmen 62 PJ-Studierende der Universitäten Hamburg und Freiburg im September 2022 teil und evaluierten das Training.Ergebnisse: Die Teilnehmenden hielten das Training zur Examensvorbereitung für sehr geeignet. Das Feedback der SPs zur Kommunikation und der Oberärztin zu den Clinical-Reasoning-Fähigkeiten erhielt in der Wichtigkeit für die Studierenden die höchsten Bewertungen. Die Teilnehmenden schätzten die Übungsmöglichkeit für strukturierte Anamneseerhebung und Fallpräsentation sehr und wünschten sich mehr solcher Angebote im Studium.Schlussfolgerung: Im telemedizinischen Training lassen sich wesentliche Elemente des Dritten Abschnitts der Ärztlichen Prüfung mit Feedback abbilden und es kann standortunabhängig angeboten werden.

Published
2023

16. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)

Author

Nagel, Gabriele, Weber, D., Fromm, E., Erhardt, S., Lübbert, M., Fiedler, W., Kindler, T., Krauter, J., Brossart, P., Kündgen, A., Salih, H. R., Westermann, J., Wulf, G., Hertenstein, B., Wattad, M., Götze, K., Kraemer, D., Heinicke, T., Girschikofsky, M., Derigs, H.G., Horst, H. A., Rudolph, C., Heuser, M., Göhring, G., Teleanu, V., Bullinger, L., Thol, F., Gaidzik, V. I., Paschka, P., Döhner, K., Ganser, A., Döhner, Hartmut, Schlenk, R. F., and German-Austrian AML Study Group (AMLSG)

Published
2017
Full Text
View/download PDF

17. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo

Author

Chaturvedi, A, Herbst, L, Pusch, S, Klett, L, Goparaju, R, Stichel, D, Kaulfuss, S, Panknin, O, Zimmermann, K, Toschi, L, Neuhaus, R, Haegebarth, A, Rehwinkel, H, Hess-Stumpp, H, Bauser, M, Bochtler, T, Struys, E A, Sharma, A, Bakkali, A, Geffers, R, Araujo-Cruz, M M, Thol, F, Gabdoulline, R, Ganser, A, Ho, A D, von Deimling, A, Rippe, K, Heuser, M, and Krämer, A

Published
2017
Full Text
View/download PDF

19. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis

Author

Thol, F, Klesse, S, Köhler, L, Gabdoulline, R, Kloos, A, Liebich, A, Wichmann, M, Chaturvedi, A, Fabisch, J, Gaidzik, V I, Paschka, P, Bullinger, L, Bug, G, Serve, H, Göhring, G, Schlegelberger, B, Lübbert, M, Kirchner, H, Wattad, M, Kraemer, D, Hertenstein, B, Heil, G, Fiedler, W, Krauter, J, Schlenk, R F, Döhner, K, Döhner, H, Ganser, A, and Heuser, M

Published
2017
Full Text
View/download PDF

21. P090 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN DAILY CLINICAL PRACTICE

Author

Schulz, F., Kellersmann, C., Betz, B., Hildebrandt, B., Thol, F., Heuser, M., Ganster, C., Beier, F., Sockel, K., Hofmann, W.-K., Kuendgen, A., Pfeilstoecker, M., Gattermann, N., Nachtkamp, K., Haase, D., and Germing, U.

Published
2023
Full Text
View/download PDF

22. P011 - Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES

Author

Bernard, E., Hasserjian, R., Greenberg, P., Ossa, J. Arango, Creignou, M., Nannya, Y., Tuechler, H., Medina-Martinez, J., Levine, M., Jädersten, M., Germing, U., Sanz, G., Van De Loosdrecht, A., Kosmider, O., Follo, M., Thol, F., Zamora, L., Pinheiro, R., Pellagatti, A., Elias, H., Haase, D., Ganster, C., Ades, L., Tobiasson, M., Palomo, L., Della Porta, M., Fenaux, P., Belickova, M., Savona, M., Klimek, V., Santos, F., Boultwood, J., Kotsianidis, I., Santini, V., Solé, F., Platzbecker, U., Heuser, M., Valent, P., Finelli, C., Voso, M.T., Shih, L.-Y., Fontenay, M., Jansen, J., Cervera-Zamora, J., Gattermann, N., Ebert, B., Bejar, R., Malcovati, L., Cazzola, M., Ogawa, S., Hellstrom-Lindberg, E., and Papaemmanuil, E.

Published
2023
Full Text
View/download PDF

23. Operative Aspekte

Author

Meyer, H.J., Chon, S.H., Voigt, C., Heuser, M., Follmann, P., Graff, H.J., Rutt, G.T., Appel, T., Schmickler, St., Geyer, G., Standl, Thomas, editor, and Lussi, Christoph, editor

Published
2012
Full Text
View/download PDF

25. DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia

Author

Gaidzik, V I, Weber, D, Paschka, P, Kaumanns, A, Krieger, S, Corbacioglu, A, Krönke, J, Kapp-Schwoerer, S, Krämer, D, Horst, H-A, Schmidt-Wolf, I, Held, G, Kündgen, A, Ringhoffer, M, Götze, K, Kindler, T, Fiedler, W, Wattad, M, Schlenk, R F, Bullinger, L, Teleanu, V, Schlegelberger, B, Thol, F, Heuser, M, Ganser, A, Döhner, H, and Döhner, K

Published
2018
Full Text
View/download PDF

27. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features

Author

Gaidzik, V I, Teleanu, V, Papaemmanuil, E, Weber, D, Paschka, P, Hahn, J, Wallrabenstein, T, Kolbinger, B, Köhne, C H, Horst, H A, Brossart, P, Held, G, Kündgen, A, Ringhoffer, M, Götze, K, Rummel, M, Gerstung, M, Campbell, P, Kraus, J M, Kestler, H A, Thol, F, Heuser, M, Schlegelberger, B, Ganser, A, Bullinger, L, Schlenk, R F, Döhner, K, and Döhner, H

Published
2016
Full Text
View/download PDF

29. GFI1 as a novel prognostic and therapeutic factor for AML/MDS

Author

Hönes, J M, Botezatu, L, Helness, A, Vadnais, C, Vassen, L, Robert, F, Hergenhan, S M, Thivakaran, A, Schütte, J, Al-Matary, Y S, Lams, R F, Fraszscak, J, Makishima, H, Radivoyevitch, T, Przychodzen, B, da Conceição Castro, S V, Görgens, A, Giebel, B, Klein-Hitpass, L, Lennartz, K, Heuser, M, Thiede, C, Ehninger, G, Dührsen, U, Maciejewski, J P, Möröy, T, and Khandanpour, C

Published
2016
Full Text
View/download PDF

30. P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA

Author

Dohner, H., primary, Montesinos, P., additional, Vives Polo, S., additional, Zarzycka, E., additional, Wang, J., additional, Bertani, G., additional, Heuser, M., additional, Calado, R., additional, Schuh, A., additional, Yeh, S.-P., additional, de la Fuente, A., additional, Cerchione, C., additional, Daigle, S., additional, Hui, J., additional, Pandya, S., additional, Gianolio, D., additional, Recher, C., additional, and de Botton, S., additional

Published
2022
Full Text
View/download PDF

31. P548: BEMCENTINIB COMBINED WITH LOW-DOSE CYTARABINE IS EFFICACIOUS AND WELL TOLERATED IN RELAPSED AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY. UPDATES FROM THE ONGOING PHASE II TRIAL (NCT02488408)

Author

Loges, S., primary, Heuser, M., additional, Chromik, J., additional, Sutamtewagul, G., additional, Kapp-Schwoerer, S., additional, Crugnola, M., additional, Di Renzo, N., additional, Lemoli, R., additional, Mattei, D., additional, Ben-Batalla, I., additional, Waizenegger, J., additional, Rieckmann, L.-M., additional, Janning, M., additional, Imbusch, C. D., additional, Beumer, N., additional, Micklem, D., additional, Gorcea-Carson, C., additional, Lawson, G., additional, Nautiyal, J., additional, Deharo, S., additional, Fiedler, W., additional, Alvarado-Valero, Y., additional, and Gjertsen, B., additional

Published
2022
Full Text
View/download PDF

32. P456: A LONG READ SEQUENCING AND CRISPR-CAS9 BASED APPROACH FOR RAPID COPY-NUMBER ALTERATION AND STRUCTURAL VARIATION DETECTION IN HEMATOLOGIC MALIGNANCIES

Author

Schrezenmeier, J., primary, Straeng, J. E., additional, Blau, O., additional, Elashy, A., additional, Lazarides, A., additional, Skambraks, S., additional, Jahn, E., additional, Gillißen, B., additional, Eckert, C., additional, Nogai, A., additional, Blau, I.-W., additional, Giannopoulos, K., additional, Heuser, M., additional, Döhner, K., additional, Bullinger, L., additional, and Dolnik, A., additional

Published
2022
Full Text
View/download PDF

33. P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE

Author

de Botton, S., primary, Choe, S., additional, Marchione, D., additional, Montesinos, P., additional, Recher, C., additional, Vives Polo, S., additional, Zarzycka, E., additional, Wang, J., additional, Bertani, G., additional, Heuser, M., additional, Calado, R., additional, Schuh, A., additional, Yeh, S.-P., additional, Hui, J., additional, Pandya, S., additional, Gianolio, D., additional, Daigle, S., additional, DiNardo, C., additional, and Dohner, H., additional

Published
2022
Full Text
View/download PDF

34. P1456: EARLY SAFETY AND CLINICAL COURSE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MEASURABLE RESIDUAL DISEASE RECEIVING GTA002, AN OFF-THE-SHELF, EX VIVO-CULTURED ALLOGENEIC NK CELL PREPARATION

Author

Heuser, M., primary, Fiedler, W., additional, Block, A., additional, de Leeuw, D. C., additional, van de Loosdrecht, A., additional, Astrid Tschan-Plessl, A., additional, Passweg, J., additional, Kloos, A., additional, Schwarzer, A., additional, Venturini, L., additional, Duru, A. D., additional, Pinkernell, K., additional, and Ganser, A., additional

Published
2022
Full Text
View/download PDF

35. S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE

Author

Hernández-Sánchez, A., primary, Villaverde-Ramiro, Á., additional, Martínez Elicegui, J., additional, González, T., additional, Benner, A., additional, Sträng, E., additional, Castellani, G., additional, Heckman, C. A., additional, Versluis, J., additional, Abáigar, M., additional, Sobas, M., additional, Azibeiro, R., additional, Tur, L., additional, Valk, P. J., additional, Metzeler, K. H., additional, Ayala, R., additional, Dall’Olio, D., additional, Tettero, J., additional, Martínez-López, J., additional, Dombret, H., additional, Pratcorona, M., additional, Damm, F., additional, Mills, K. I., additional, Mayer, J., additional, Thiede, C., additional, Voso, M. T., additional, Sanz, G. F., additional, Calado, F., additional, Döhner, K., additional, Gaidzik, V. I., additional, Heuser, M., additional, Haferlach, T., additional, Turki, A. T., additional, Reinhardt, D., additional, Villoria Medina, R., additional, van Speybroeck, M., additional, Schulze-Rath, R., additional, Barbus, M., additional, Butler, J. E., additional, Hernández Rivas, J. M., additional, Huntly, B. J., additional, Ossenkoppele, G. J., additional, Döhner, H., additional, and Bullinger, L., additional

Published
2022
Full Text
View/download PDF

37. P556: CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB + AZACITIDINE OR PLACEBO + AZACITIDINE

Author

Schuh, A., primary, de Botton, S., additional, Recher, C., additional, Vives Polo, S., additional, Zarzycka, E., additional, Wang, J., additional, Bertani, G., additional, Heuser, M., additional, Calado, R., additional, Yeh, S.-P., additional, Hui, J., additional, Pandya, S., additional, Gianolio, D., additional, Chamberlain, C., additional, Dohner, H., additional, and Montesinos, P., additional

Published
2022
Full Text
View/download PDF

38. P1024: IMPACT OF TP53 IN MYELOFIBROSIS UNDERGOING STEM CELL TRANSPLANTATION

Author

Gagelmann, N., primary, Badbaran, A., additional, Panagiota, V., additional, Wolschke, C., additional, Ayuk, F., additional, Thol, F., additional, Ditschkowski, M., additional, Cassinat, B., additional, Robin, M., additional, Schroeder, T., additional, Heuser, M., additional, Reinhardt, H. C., additional, and Kröger, N., additional

Published
2022
Full Text
View/download PDF

40. P468: MRD AS A BIOMARKER FOR RESPONSE TO DONOR LYMPHOCYTE INFUSION AFTER AL-LOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Author

Teich, K., primary, Stadler, M., additional, Gabdoulline, R., additional, Wienecke, C., additional, Heida, B., additional, Klement, P., additional, Büttner, K., additional, Venturini, L., additional, Wichmann, M., additional, Puppe, W., additional, Schultze-Florey, C., additional, Beutel, G., additional, Eder, M., additional, Ganser, A., additional, Heuser, M., additional, and Thol, F., additional

Published
2022
Full Text
View/download PDF

41. P561: VIALE-T: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF VENETOCLAX IN COMBINATION WITH AZACITIDINE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

Author

Craddock, C., primary, Platzbecker, U., additional, Heuser, M., additional, Pullarkat, V., additional, Chaudhury, S., additional, Wu, D., additional, Addo, S., additional, Chyla, B., additional, Jiang, Q., additional, Lee, P., additional, and Wolff, J. E., additional

Published
2022
Full Text
View/download PDF

42. P466: AMPLIFIED EPOR/JAK2 GENES DEFINE A UNIQUE SUBTYPE OF ACUTE ERYTHROID LEUKEMIA

Author

Takeda, J., primary, Yoshida, K., additional, Nakagawa, M., additional, Nannya, Y., additional, Yoda, A., additional, Saiki, R., additional, Ochi, Y., additional, Zhao, L., additional, Okuda, R., additional, Qi, X., additional, Mori, T., additional, Kon, A., additional, Chiba, K., additional, Tanaka, H., additional, Shiraishi, Y., additional, Kuo, M.-C., additional, Kerr, C., additional, Nagata, Y., additional, Morishita, D., additional, Hiramoto, N., additional, Hangaishi, A., additional, Nakazawa, H., additional, Ishiyama, K., additional, Miyano, S., additional, Chiba, S., additional, Miyazaki, Y., additional, Kitano, T., additional, Usuki, K., additional, Sezaki, N., additional, Tsurumi, H., additional, Miyawaki, S., additional, Maciejewski, J., additional, Ishikawa, T., additional, Ohyashiki, K., additional, Ganser, A., additional, Heuser, M., additional, Thol, F., additional, Shih, L.-Y., additional, Takaori−Kondo, A., additional, Makishima, H., additional, and Ogawa, S., additional

Published
2022
Full Text
View/download PDF

43. P448: PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA

Author

Ruecker, F. G., primary, Corbacioglu, A., additional, Theis, F., additional, Christopeit, M., additional, Germing, U., additional, Wulf, G., additional, Abu Samra, M., additional, Teichmann, L., additional, Lübbert, M., additional, Kühn, M. W., additional, Bentz, M., additional, Westermann, J., additional, Bullinger, L., additional, Gaidzik, V. I., additional, Jahn, E., additional, Gröger, M., additional, Kapp-Schwoerer, S., additional, Weber, D., additional, Thol, F., additional, Heuser, M., additional, Ganser, A., additional, Döhner, H., additional, and Döhner, K., additional

Published
2022
Full Text
View/download PDF

44. P478: THE GERMLINE VARIANT GFI1-36N PROMOTES GENETIC INSTABILITY IN LEUKEMIC CELLS AND OPENS NEW THERAPEUTIC APPROACHES FOR ABOUT 15% OF ALL AML PATIENTS

Author

Vorwerk, J., primary, Frank, D., additional, Sun, K., additional, Neumannn, F., additional, Heuser, M., additional, Kunadt, D., additional, Berdel, W. E., additional, Mikesch, J.-H., additional, Schliemann, C., additional, Lenz, G., additional, Jayavelu, A. K., additional, and Khandanpour, C., additional

Published
2022
Full Text
View/download PDF

46. Managing hematological cancer patients during the COVID-19 pandemic:an ESMO-EHA Interdisciplinary Expert Consensus

Author

Buske, C., Dreyling, M., Alvarez-Larrán, A., Apperley, J., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Giovanni Della Porta, M., Dimopoulos, M., D'Sa, S., Eich, H. T., Foà, R., Ghia, P., da Silva, M. G., Gribben, J., Hajek, R., Harrison, C., Heuser, M., Kiesewetter, B., Kiladjian, J. J., Kröger, N., Moreau, P., Passweg, J. R., Peyvandi, F., Rea, D., Ribera, J. M., Robak, T., San-Miguel, J. F., Santini, V., Sanz, G., Sonneveld, P., von Lilienfeld-Toal, M., Wendtner, C., Pentheroudakis, G., Passamonti, F., Buske, C., Dreyling, M., Alvarez-Larrán, A., Apperley, J., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Giovanni Della Porta, M., Dimopoulos, M., D'Sa, S., Eich, H. T., Foà, R., Ghia, P., da Silva, M. G., Gribben, J., Hajek, R., Harrison, C., Heuser, M., Kiesewetter, B., Kiladjian, J. J., Kröger, N., Moreau, P., Passweg, J. R., Peyvandi, F., Rea, D., Ribera, J. M., Robak, T., San-Miguel, J. F., Santini, V., Sanz, G., Sonneveld, P., von Lilienfeld-Toal, M., Wendtner, C., Pentheroudakis, G., and Passamonti, F.

Abstract

Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. Methods: This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. Results and conclusion: The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.

Published
2022

47. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy

Author

Wang, E, Montesinos, P, Minden, M, Lee, J, Heuser, M, Naoe, T, Chou, W, Laribi, K, Esteve, J, Altman, J, Havelange, V, Watson, A, Gambacorti-Passerini, C, Patkowska, E, Liu, S, Ruishan, W, Philipose, N, Hill, J, Gill, S, Rich, E, Tiu, R, Wang, Eunice S, Montesinos, Pau, Minden, Mark D, Lee, Je-Hwan, Heuser, Michael, Naoe, Tomoki, Chou, Wen-Chien, Laribi, Kamel, Esteve, Jordi, Altman, Jessica K, Havelange, Violaine, Watson, Anne-Marie, Gambacorti-Passerini, Carlo, Patkowska, Elzbieta, Liu, Shufang, Wu, Ruishan, Philipose, Nisha, Hill, Jason E, Gill, Stanley C, Rich, Elizabeth Shima, Tiu, Ramon V, Wang, E, Montesinos, P, Minden, M, Lee, J, Heuser, M, Naoe, T, Chou, W, Laribi, K, Esteve, J, Altman, J, Havelange, V, Watson, A, Gambacorti-Passerini, C, Patkowska, E, Liu, S, Ruishan, W, Philipose, N, Hill, J, Gill, S, Rich, E, Tiu, R, Wang, Eunice S, Montesinos, Pau, Minden, Mark D, Lee, Je-Hwan, Heuser, Michael, Naoe, Tomoki, Chou, Wen-Chien, Laribi, Kamel, Esteve, Jordi, Altman, Jessica K, Havelange, Violaine, Watson, Anne-Marie, Gambacorti-Passerini, Carlo, Patkowska, Elzbieta, Liu, Shufang, Wu, Ruishan, Philipose, Nisha, Hill, Jason E, Gill, Stanley C, Rich, Elizabeth Shima, and Tiu, Ramon V

Abstract

Treatment results for patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated (FLT3mut+) acute myeloid leukemia (AML) ineligible for intensive chemotherapy are disappointing. This multicenter, open-label, phase 3 trial randomized (2:1) untreated adults with FLT3mut+ AML ineligible for intensive induction chemotherapy to receive gilteritinib (120 mg/d orally) and azacitidine (GIL + AZA) or azacitidine (AZA) alone. The primary end point was overall survival (OS). At the interim analysis (August 26, 2020), a total of 123 patients were randomized to treatment (GIL + AZA, n = 74; AZA, n = 49). Subsequent AML therapy, including FLT3 inhibitors, was received by 20.3% (GIL + AZA) and 44.9% (AZA) of patients. Median OS was 9.82 (GIL + AZA) and 8.87 (AZA) months (hazard ratio, 0.916; 95% CI, 0.529-1.585; P = .753). The study was closed based on the protocol-specified boundary for futility. Median event-free survival was 0.03 month in both arms. Event-free survival defined by using composite complete remission (CRc) was 4.53 months for GIL + AZA and 0.03 month for AZA (hazard ratio, 0.686; 95% CI, 0.433-1.087; P = .156). CRc rates were 58.1% (GIL + AZA) and 26.5% (AZA) (difference, 31.4%; 95% CI, 13.1-49.7; P < .001). Adverse event (AE) rates were similar for GIL + AZA (100%) and AZA (95.7%); grade ≥3 AEs were 95.9% and 89.4%, respectively. Common AEs with GIL + AZA included pyrexia (47.9%) and diarrhea (38.4%). Gilteritinib steady-state trough concentrations did not differ between GIL + AZA and gilteritinib. GIL + AZA resulted in significantly higher CRc rates, although similar OS compared with AZA. Results support the safety/tolerability and clinical activity of upfront therapy with GIL + AZA in older/unfit patients with FLT3mut+ AML. This trial was registered at www.clinicaltrials.gov as #NCT02752035.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results